GENE ONLINE|News &
Opinion
Blog

2024-03-06|

Hummingbird Bioscience to Present Two Posters on Anti-HER3 and Anti-VISTA Antibody Therapeutics at American Association for Cancer Research (AACR) Meeting 2024

by GeneOnline
Share To
  • Presentations will highlight the broad potential treatment opportunities for its clinical-stage targeted therapeutics HMBD-001 (anti-HER3 mAb) and HMBD-002 (anti-VISTA mAb) with further demonstrations of their pre-clinical efficacy in additional indications and deeper studies of their underlying therapeutic mechanisms
  • HMBD-001 may represent a viable targeted treatment option in patients with oncogenic HER3 mutations across cancer types
  • Understanding the mechanisms driving HMBD-002’s potent anti-tumor activity enhances the current knowledge of VISTA biology and improves the understanding of which patients may benefit most from HMBD-002

SAN FRANCISCO and HOUSTON and SINGAPORE, March 6, 2024 /PRNewswire/ — Hummingbird Bioscience, a data-driven precision biotherapeutics company discovering and developing transformative biologic medicines for hard-to-treat diseases, today announced two upcoming poster presentations at the American Association for Cancer Research (AACR) Meeting 2024 (April 5-10) in San Diego, California.  

The company will present pre-clinical data describing the activity of HMBD-001, a clinical-stage anti-HER3 monoclonal antibody (mAb) currently in Phase I trials (NCT05057013NCT05910827 and NCT05919537), in tumors with oncogenic HER3 mutations, and pre-clinical data investigating the mechanism of action and anti-tumor response of HMBD-002, a clinical-stage anti-VISTA mAb currently in Phase I trials (NCT05082610).

HMBD-001 is shown to potently block oncogenic signaling driven by HER3 mutations and could offer significant clinical benefit for patients with HER3 mutations across cancer types. The poster will highlight that more than 80% tumor growth inhibition is seen across multiple preclinical models with common HER3 mutations. The data also confirms that HMBD-001’s binding epitope does not overlap with these mutations in HER3.

HMBD-002 selectively blocks VISTA while avoiding depletion of important immune cell populations, holding significant promise for patients with aggressive cancers, including triple-negative breast cancer and non-small cell lung cancer. The HMBD-002 poster will highlight the molecular and cellular mechanisms driving HMBD-002’s specific and potent anti-tumor response via VISTA blockade. These insights will help to identify and target patients that are most likely to benefit from HMBD-002.

“These translational studies exemplify Hummingbird Bio’s commitment to precision oncology. Through better understanding of disease biology and the mechanisms underlying the efficacy of our therapies, we can more precisely define the patient populations that will benefit from those therapies. We look forward to discussing our recent advancements with the oncology research community at AACR,” said Jerome Boyd-Kirkup, Ph.D., Chief Scientific Officer, Hummingbird Bioscience.

Hummingbird Bioscience is recruiting patients with aberrant HER3 signaling, which includes selected HER3 mutations, in the company’s ongoing Phase Ib trial (NCT05919537).

©www.geneonline.com All rights reserved. Collaborate with us: service@geneonlineasia.com
Related Post
R&D
Innovating Prostate Cancer Care: SYNC-T, Proteogenomics, and Culturally Tailored Education at AACR 2024
2024-04-10
Antengene to Present Four Preclinical Abstracts at AACR 2024, Highlighting Focus on Cancer Immunology, Targeted Agents and Novel Technology Platforms
2024-03-06
Moderna’s Cancer Vaccine to Enter Phase 3 Trials This Year
2023-04-17
LATEST
Ochre Bio Announces Partnership with Boehringer Ingelheim to Develop Novel Regenerative Treatments for Patients with Advanced Liver Disease
2024-04-22
Earth Day Awareness: Hospitals Embrace Sustainability Efforts
2024-04-22
WHO Raises Alarm: Bird Flu Threat to Humans an ‘Enormous Concern’
2024-04-19
The Legal Battlefield of Weight-Loss Drugs: Eli Lilly and Novo Nordisk on the Defensive
2024-04-18
Pharmacogenomics in Asia-Pacific: Nalagenetics CEO Levana Sani Offers Insights and Strategies
2024-04-17
Rice University Engineers Develop Miniature Brain Stimulator for Safer and Less-invasive Neuromodulation
2024-04-17
Breakthrough Screening Platform to Assess SARS-CoV-2 Mutations and Potential Treatments
2024-04-16
EVENT
2024-04-27
2024 Biomedical Final Pitch Competition
Room DA1620, Dana Building, Dana-Farber Cancer Institute, 99 Jimmy Fund Way, Boston, MA 02115
Scroll to Top